given macro uncertainti run rate profit
recoveri cyclic appear elus expect investor
focu estim impli recoveri
expect spread valuat cyclic
defens unwind leav place hide
place hide given high degre uncertainti limit order book
visibl lack momentum across cyclic end market
unsurpris rel spread valuat cyclic valu
defens qualiti remain widest recent histori certainli leav
place hide think cyclic
littl momentum disast investor
may fear instanc spread deterior
period rais question run rate profit
defens like continu show yoy growth although comp
get tougher neg share price reaction profit warn chr
hansen novozym suggest current valuat leav littl room
disappoint recoveri longer expect expect
investor attent start shift recoveri impli estim
unlik come result wait see whether
compani adjust invest schedul therefor capit
alloc approach light slower growth environ
spread remain depress weak demand trade tension modest
recoveri spread start quarter product mdi
siloxan spread revert back januari low trade
tariff increas may spread except
acryl trend lower enter although tent
sign may found floor spread pmdi tdi asia stabl
show small sequenti improv recent week question
whether compani take pro activ approach rationalis suppli and/or
suppli addit whether healthi balanc sheet allow defer
tactic view quarter quarter convict hard come
believ within cyclic evonik overweight well place deliv
expect sequenti qoq improv lanxess equal-weight
also like track meet guidanc bromin chain
remain well support liquid overweight continu see good top
line momentum margin improv yoy respect
initi expect repres catalyst umicor
underweight given recent profit warn deterior end
market rais tail risk estim may rais concern around
leverag estim still see risk disappoint
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
victrex underweight relat expect given continu
trade histor averag croda overweight anoth name
expect challeng although given recent under-perform
think well understood market would look buy
increment weak view earn improv
sequenti bolt-on underappreci balanc sheet
present option wildcard quarter wacker equal-weight
think green shoot like disproportion reward
given depress sentiment estim
exhibit chang compani
chang base
chang base
chang base
chang base
chang base
chang
chang
chang
chang
compani guid
exhibit guidanc compani
liquid confid abil deliv net profit growth calcul constant exchang rate
deliv toward strategi continu creat fit purpos organis focus paint
coat compani contribut achiev guidanc demand trend differ per region
segment uncertain macroeconomic environ raw materi inflat expect continu
although lower rate robust price inti cost save program place
address current challeng
financi perform high level achiev ebitda compar record level
slight declin sale compar full year ebit special item expect
prior-year level roce slightli higher cost capit percentag slightli level
return capit employ roce expect declin consider compar previou year
volum growth capital-expenditure tax rate financi result
progress expect improv free cash flow continu invest futur
high singl digit increas adjust ebitda compar prior year adjust ebitda pre-vitamin effect
togeth improv adj net oper exclud impact
downgrad
ag ebitda least stabl significantli higher exclud methacryl busi ebitda
nutrit slightli lower slightli higher perf materi around level last year
financi object averag organ sale growth year period
outlook oper perform within medium term guidanc mid high singl digit growth
improv averag work capit day exclud preciou metal capital-expenditure
fy ebitda pre guidanc
organ growth ebitda margin around exclud ifr despit econom slowdown
ebit full year rang
group sale expect grow mid singl digit percentag ebitda like declin
exhibit eu chem push higher rel european
exhibit rel valuat eu chem cyclic vs
defens remain low yr forward pe
morgan stanley research averag premium price-to-earnings dy price-to-book
exhibit eu chem close correl auto
exhibit eu chem rel perform diverg ep
exhibit sector decoupl composit pmi
exhibit price volum significantli weaken vs
euroland world
select move product spread
exhibit asia pmdi spread pick recent low
exhibit asia tdi spread remain cycl low
asian pmdi spread benzen
asia tdi toluen /t
exhibit polycarbon resin spread continu weaken
exhibit tight adn keep spread elev level
exhibit mma spread start correct sharpli
raw materi aceton methanol
follow pre-commun earlier month expect
liquid underli busi environ remain intact perform
broadli similar forecast sale ebitda
translat ebit impli oper margin yoy
improv basi point expect ebit period
relat forecast group sale gase servic expect
sale organ growth engin construct
forecast sale yoy gm sale also yoy
compani pre-communiqu fx quarter
year addit liquid expect energi pass-through
quarter broadli neutral techair drive portfolio
division li forecast sale organ growth driven
hydrogen startup project well contribut fujian expect see
anoth solid quarter electron sale organ growth
driven posit mix effect cryogen gase well specialti gase advanc
materi continu grow strongli expect small sequenti pick-up industri
merchant volum weaker europ well continu stabl market
condit asia us contribut organ growth sale
benefit acquisit tech lastli healthcar expect
organ growth sale low impact acquisit
els look comment around margin expans
gase servic perhap importantli scope improv roce
guidanc whether capital-expenditure like move higher growth opportun acceler
increas order backlog engin activ given current stage
capital-expenditure cycl time on-going new project ramp insight ip
develop region extent al growth prospect via new
busi opportun delink materi slowdown due invest
cycl build
exhibit updat price target liquid
rais price target previous back incorpor
techair acquisit synergi well mark market current peer
expect similar trend compar price momentum still
posit thank higher run rate price volum remain neg account
activ bottom slice soft underli market dynam part perform
coat well china deco group level forecast sale yoy
con driven price initi offset volum
loss unfavour fx raw materi cost inflat yoy still modest
headwind quarter although expect level lower run rate seen
previou two quarter ebit estim vs con
division level perform coat expect sale price
vol fx driven soft volum industri coat inflect
point marin partial off-set stabl growth powder coat well
usual season estim ebit impli margin yoy
decor paint expect sale price vol fx
pricing/mix remain posit region volum mix weak
china offset stabl posit pictur europ america
underli sale latam mostli brazil remain solid suffer brl/eur
translat think expect ebit margin yoy repres
ebit
els look expect see signific cash outflow relat
buy-back program financi gain sale slough
manufactur facil book number well howev investor
like continu focu outlook consensu look ebit
progress yoy like critic quarter achiev show
meaning progress target
arkema guid ebitda compar level includ ifr
although expect growth weight expect weaker auto
consum electron demand continu impact growth industri specialti
softer yoy mma spread continu normalis hpm condit like
similar seen coat solut see improv well
season stronger second half benefit ramp
sartom expans end acryl expans around
ebitda acryl acid jv group forecast sale
ebitda con
across divis industri specialti expect ebitda
main driver declin outsid weaker auto consum electron
demand record volum fluorogas normalis mma spread
coat solut forecast ebitda small improv good
volum acryl monom improv downstream margin
season stronger quarter high perform materi expect trade
condit remain similar forecast ebitda
increment margin improv expect price increas addit molecul
off-set raw materi price increas phase throughout year
els look look clarif compani capit
alloc prioriti get closer market expect remain
significantli compani target achiev sale margin
bloomberg con current look ebitda versu impli
target arkema capit alloc strategi current priorit invest
capital-expenditure mainten growth well larger project dividend next
consider final portfolio manag reiter manag recent
cbr trip interestingli met manag june compani
indic see room dividend growth rel peer
exhibit mma spread begun normalis
raw materi aceton methanol
alreadi pre-warn quarter compani expect ebit pre
except yoy driven primarili significantli weaker
result chemic headwind cracker turnaround well weaker
cracker margin materi weaker isocyan price agricultur solut us
weather trade conflict off-set basf note realis yoy
increas industri solut consider surfac technolog slight
nutrit slight forecast group sale ebit pre
except across divis forecast chemic ebit
yoy reflect turn around weaker product margin materi
expect ebit sequenti declin isocyan price spread
continu weigh industri specialti forecast ebit higher price
continu support surfac nutrit forecast
slight improv respect agricultur solut
estim ebit period weak us season reduc number
crop protect applic period line estim ebit
els look given softer expect start year investor
focu updat outlook addit granular
current run rate profit leav us guidanc rang
yoy ebit also expect investor seek better understand bridg
term temporari headwind repeat cracker turnaround bayer
servic agreement etc like net contribut save program
may soon compani comment subject would expect
updat plan asset dispos interest
macro environ remain challeng limit visibl sign
improv vs last quarter linger lower product spread continu weak
covestro end market includ auto electron lead us forecast
sale yoy vs vara con ebitda vs
con line compani guidanc result
similar level rang like toward middl
rang
division expect pur weakest segment given persist weak
mdi tdi spread although us construct furnitur demand posit
forecast pur sale vs con adj ebitda vs con
pc expect sale fall yoy vs con due
soft auto electron market adj ebitda final expect ca
sale yoy vs con adj ebitda margin
yoy vs con neg mix effect soft coat market
els look may see modest raw materi relief ca
hdma normalis given soft auto demand could provid relief adn
therefor hdma otherwis focu manag commentari relat
current trade environ particularli run rate profit underli
demand chang capit alloc approach covestro peer
relat capac addit
lower price target second half recoveri appear
elus reduc ep estim mark market
current price spread mdi tdi pc led us lower target
price deriv weight averag sotp dcf ddm residu incom
continu believ stock offer deep valu trade
ev/ebitda offer dividend yield howev acknowledg
absenc earn momentum sustain re-rat unlik without chang
exhibit risk reward posit skew share offer
expect sequenti softer croda slow growth trend
care off-set resili life scienc busi group forecast sale
equat organ growth across segment expect
organ growth person divis face tough comp
backdrop weaker macro trend north america europ well
potenti disrupt asian on-line sell platform hand life
scienc forecast growth incl portfolio effect biosector
healthi underli demand continu margin progress lastli within process
technolog margin expect larg stabl region weak
europ biggest drag felt auto market forecast slight organ
growth forecast group ebit impli margin
decreas yoy pbt period base case
forecast interim dividend factor note forecast
increas non-capitalis interest headwind delay ramp
atla point carri cost plant impact
exhibit mse pbt bridg impli flat growth first half
els look particularli interest three point
confirm ramp biosurfact plant us updat
estim yoy contribut given issu occur late plan
bolt-on technolog acquisit insight recent acquisit
fare particular biosector plant impact updat free cash posit
capit alloc half year stage
made small adjust base case price target previous
account modest chang earn estim
acknowledg first half croda like somewhat lacklustr
organ growth perspect believ well understood market given
recent under-perform remain view present compel
entri point compani set deliv sequenti improv second half
certain headwind becom tailwind well underappreci contribut
come bolt-on acquisiton fulli reflect valuat
estim
exhibit croda share price recent under-perform
expect look similar saw materi improv
second quarter due season stronger quarter still like yoy
construct auto continu weigh volum nutrit expect
impact asf continu group sale expos swine feed
china howev saw localis volum declin like
off-set export region altern protein consumpt exampl
poultri compani guid high singl digit underli ebitda growth mse
includ ifr benefit growth andr pectin also
consolid march onward comment refer underli ebitda
exclud sale ebitda benefit vitamin price
volum fx big benefit
quarter expect dsm report sale con
ebitda includ quarterli benefit ifr con
across segment expect nutrit sale vs con driven
volum growth decreas price underli price
unwind vitamin benefit forecast nutrit ebitda
con expect continu volum growth anim
nutrit forecast declin price anim nutrit declin
perform materi expect sale
volum growth fx impact price ebitda con
respect
els look expect anyth result given
buy-back announc see dsm balanc sheet potenti sourc
option given dsm low level net debt ebitda compani previous
suggest could small big focus area human nutrit
separ across nutrit expect anim nutrit show stronger growth
human nutrit quarter could perceiv investor soft
littl come surpris relat given compani recent profit
warn state ebitda versu previous guid
sequenti improv downgrad guidanc larg consequ
deterior silicon market follow new tariff us import china
delay restart roussillon upstream silicon plant franc mainten stop
may weaker market sentiment silicon metal ferrosilicon term
ebitda period forecast nok bbg con nok
division silicon forecast ebitda nok margin
silicon materi forecast ebitda nok reflect soft volum
price foundri product expect ebitda nok carbon nok
former impact slow automot demand
els look investor like focu exit run rate
profit divis relat expect underli demand trend
quantif roussillon impact quarter updat relat
expect capac addit upstream silicon elkem
expect earn repres sequenti improv group level
segment market remain challeng particularli auto evonik exposur
auto learnt cannonbal trip june compani confid
deliv cost save volum remain healthi nutrit
raw materi outag issu saw perform materi
resolv impact guidanc ebitda least
stabl least ebitda con current look
growth support ramp methionin volum eas comp
cost cut peroxychem although includ guidanc
quarter forecast sale vara con ebitda
vara con across divis resourc effici forecast
ebitda sale nutrit forecast ebitda
includ impact ramp cost associ methionin plant
come on-line methionin price weaken vs howev
volum remain strong forecast division sale
perform materi market remain tough howev expect sequenti
improv raw materi issu resolv forecast
sale ebitda forecast servic
els look flow remain focu investor compani
guid signific improv year year season weak quarter
payment variabl compens howev expect cta benefit
ifr
expect organ growth look similar saw
ebitda line con think qualiti ebitda may slightli lower
expect ifr ebitda benefit half term top line trade
condit remain strong compani guid pass
absolut raw materi price increas forecast organ growth con
start see sign weak consum
environ nielsen data show deterior recent month dont
expect reflect givaudan top line forecast sale
half con quarter ebitda
half repres margin con ebitda
across divis expect fragranc sale sale
driven organ growth fx acquisit impact express
parfume small impact naturex expect price increas continu
off-set raw materi price increas although would highlight report
fragranc margin yoy forecast fragranc ebitda
flavour forecast sale sale driven
organ growth fx impact acquisit naturex forecast ebitda
els look line con ebitda level expect
ep disappoint compani guid sale
report sale howev includ
sale zic exclud sale would fallen
target note con current fcf-sale improv
cash gener would expect share could under-perform
addit cash inflow sale zic
appear start weaker previous expect address
june due soft multi-national volum tast continu
pressur ingredi concentr citra like result peer
normalis suppli chain post frutarom acquisit weak pti protein
technolog ingredi within savori solut natur color raw materi
driven price decreas given slower expect start growth like
weight comp eas see increas benefit recent price
realis scent cost/synergi ramp recent benefit growth
year includ addit advantag dec mighti jan leagel march
arybal april wiberg may forecast sale ebitda
adjust ep
across divis tast forecast organ growth similar
seen due soft multi-national volum forecast ebit
repres ebitda margin scent expect price increas
continu help off-set raw materi inflat howev weak fragranc
ingredi volum weigh organ growth forecast organ growth
sale forecast ebit repres margin
frutarom recent quarter organ growth focu initi expect
organ growth howev sinc acquir frutarom report
two quarter organ growth expect organ growth slow
versu org growth org growth could somewhat
disappoint market forecast ebit repres margin
els look top line synergi guid
deliv date progress import increas
convict deliveri guidanc look reconfirm
guidanc follow slow start year guidanc sale
impli growth organ top-line synergi
adj ep ep exclud amort con
exhibit mse versu consensu guidanc
lanxess recent confirm ebitda guidanc
cannonbal trip previous guid compani expect
challeng year driven tougher macro environ far compani
seen materi improv deterior aggreg us still show
growth china ex-auto still ok although yet seen uptick
consum spend follow recent chines govern stimulu said ceo
think opportun demonstr resili portfolio
expect ebitda higher yoy driven improv advanc
materi stabil perform chemic specialti addit off-set
weak engin materi
forecast sale ebitda includ ifr benefit
around per quarter expect advanc materi stand
segment driven improv saltigo well organ growth driven
previou invest debottlenecking/brownfield capital-expenditure forecast ebitda
specialti addit expect ebitda similar level
weak rhein chemi like off-set bromin price synergi
forecast ebitda perform chemic forecast ebitda
expect engin materi weaker yoy due higher exposur
els look lanxess state plan chang structur
next year part plan given proce arlanxeo
expect divestitur and/or acquisit signific driver busi go
forward near term compani abil deliv synergi
oper effici price power focu weaker trend
auto construct also remain theme addit ebitda
in-lin like think investor may find ebitda
guidanc around previou year level conserv comp get easier throughout
year
expect strong organ growth continu symris although slower
pace first quarter mse org growth fx driven good
underli volum growth support new cosmet ingredi facil us
start new flavour site china continu price increas
particularli menthol group expect sale line
consensu expect forecast ebitda includ ifr
impact full year repres ebitda margin
across divis quarter forecast scent sale driven
price volum sale expect ebitda
con throughout scent top line growth impact
market price citral chain basf forc majeur ludwigshaufen
site environment reform china contribut steep price increas
citral symris backward integr l-menthol lanxess wasnt
custom contract began roll compani abl
pass price increas therefor expect symris achiev strong price scent
may normalis howev expect menthol
expans come on-line support volum flavour expect sale
quarter half ebitda con
nutrit forecast sale quarter half
ebitda half line con
els look updat expect time closur
adf/idf acquisit updat raw materi inflat impact margin
consum demand natur ingredi product consum
limit avail certain natur raw materi expect raw materi
inflat continu higher rate go forward symris previous guid
toward raw materi inflat
consensu estim vara research forecast sale yoy
increas underli ebitda impli margin
yoy across divis expect advanc materi divis
weakest perform busi unit consensu forecast drop underli
ebitda believ driven weaker auto electron
market off-set strong demand composit consensu expect advanc
formul broadli flat yoy underli ebitda weaker
off-set posit momentum mine aroma think consensu
forecast perform chemic strongest divis deliv underli
ebitda growth like driven higher contract price soda
solid peroxid demand ex-china
els look market remain weak
novecar see improv new busi initi easier
compar overal critic oil price uptick activ typic sit
solvay see tangibl improv work capit
driven variou initi includ streamlin suppli chain process
import catalyst year probabl announc new
strategi expect new ceo set ambit target
midterm compani indic could includ redefin bonu
structur across organis increas emphasi cash flow gener
given synthom propos acquisit omnova announc recent
expect much market focu remain futur pro-forma synthom
busi rather near term result unlik previou year earn
season weight first half year compani said expect
equally-weight half year driven raw materi deflat time
ramp pasir gudang plant throughout year believ trade condit
continu prove challeng follow slow start year
therefor forecast sale pbt yoy decreas
respect division expect weak sbr market drive low growth
perform elastom off-set stronger nitril busi asia industri
specialti expect weak function solut dispers anticip
slower yoy given euro-centr busi gear toward coat
textil adhes construct market across pe fs compani expect
margin higher yoy unchang therefor forecast group ebita
margin yoy
els look mention strateg financi updat
omnova deal updat board expect mse pbt
vs con howev comment run rate demand
interest updat relat nitril capac ramp-up synthom
follow compani profit warn april recur ebit guidanc
rang come forecast group
sale vs con recur ebit incl associ
con driven weak auto electron demand plan
mainten stop hoboken materi lower cobalt price slower rate
growth ev off-set part fx tailwind higher preciou metal st
expect sale fall yoy division rebit vs con
see slower growth ev cathod materi weaker consum
electron demand lco materi lower cobalt price recycl forecast
sale division rebit vs con reflect
higher metal price averag off-set plan mainten shutdown
occur catalysi see sale division rebit
con reflect limit regul overlay loss diesel market share
soft auto market
els look expect investor focu guidanc given
recoveri yet key end market umicor incorpor
headwind recent fire incid hoboken beyond market
focu cash flow term capital-expenditure work capit well updat
cathod market includ time-frame ramp compani cathod
capac expans overal believ particular ebit consensu
still look ambiti given lacklust auto market cathod risk uncertainti
slow industri electron activ
weak underli vol expect volum soft continu
second half given on-going challeng auto electron particular valu ad
re-sel larg proport expos china compani
provid im forecast sale volum yoy
could rais question con pbt expect well
compani visibl relat beyond run rate volum expect market
pay close attent manag comment around impli margin
recoveri well free cash flow remain view special dividend
unlik reduc impli dividend yield
els look littl inform provid im expect
market pay close attent volum outlook across victrex
cyclic market updat work capit brexit destocking/stock effect
commentari futur cash gener given previous announc special div
cut updat mega programm invest guidanc
debottleneck capac capital-expenditure
reduc pt reduc volum
expect light continu weak auto electron
increasingli oil ga relat peek demand
exhibit risk still gear downsid
wacker face tough backdrop particular polysilicon price continu
deterior forecast ebitda lower yoy vs
consensu driven lower price polysilicon upstream silicon
partial mitig cost cut initi forecast sale vs
consensu lower commod price larg off-set volum
growth favour fx season improv polym
division level expect polysilicon weakest perform forecast
polysilicon sale fall yoy vs consensu due
deflationari price pv grade poli ebitda loss vs consensu
polym see sale vs consensu ebitda
vs consensu posit mix effect normal season
improv qoq biosolut expect continu strong sale growth
yoy vs consensu ebitda vs consensu
silicon expect sale broadli flat yoy vs consensu
ebitda yoy vs consensu due weak
standard price particularli asia
els look expect market focu full year guidanc
current call mid-single-digit growth sale ebitda declin
yoy updat time magnitud potenti insur
payment polysilicon silicon market updat well balanc sheet
health cash flow
price lower reduc ep estim
back mark market current price polysilicon
silicon well mark market current valu wacker siltron stake
cut reduc pt accordingli bear case remain unchang
reflect discount book valu account write-down risk polysilicon
inventori current market price reduc bull case reflect
reset near term polysilicon profit assumpt risk reward
posit skew remain cautiou polysilicon market time given
market uncertainti persist therefor remain equal-weight
product chemic inc
latest report european quantit strategi strategist market factor
chartbook team highlight key observ month factor rank
efficaci valuat sentiment industri factor view base
dimens framework composit rank dimens indic
least favour factor time addit base two level factor
classif infer recommend factor factor categori detail
explan approach factor invest integr approach
factor perform june last month observ europ revers
acut risk-off environ may momentum volume correct
valu stop declin qualiti rose slightli
factor perform around qe announc ahead much
anticip qe announc euro area around like fed rate cut
explor short term effect announc region found valu
tend under-perform far ahead announc rebound strongli close
event volume momentum qualiti tend under-perform
shortli qe announc
dimens updat rank factor subgroup remain stabl
compar month ago still neg composit momentum
rank maintain current posit view defens valu overal
factor recommend line late cycl macro backdrop integr
extrem valuat spread qualiti valu overbought level
latest factor view follow
defens valu overal profil defens valu attract
 momentum overview factor show high sentiment overbought
high valuat bad posit high crowd case normal market
posit yield overal profil attract posit expos
deterior macro backdrop
exhibit summari ms factor
factset morgan stanley research composit rank
deriv averag rank dimens framework
subgroup select least favour categori
time indic lower valu prefer
factset morgan stanley research analysi expos expos
null score set neutral
factset morgan stanley research analysi expos expos
null score set neutral
factset morgan stanley research analysi expos expos
null score set neutral
factset morgan stanley research analysi expos expos
null score set neutral
factset morgan stanley research analysi expos expos
null score set neutral
factset morgan stanley research analysi expos expos
null score set neutral
valuat methodolog risk
price target set use blend dcf wacc t-growth
residu incom assumpt dcf spot peer multipl ddm
upsid risk increas inflat higher capital-expenditure custom higher industri
downsid risk global recess lower utilis rate custom larg
industri failur deliv synergi guid post airga deal
valuat thesi price target base blend averag dcf
wacc t-growth residu incom assumpt dcf ddm
coe t-growth sotp base peer
demand and/or fewer capac addit full deliveri save increas dividend
demand and/or new capac addit fail deliveri save china slowdown
valuat thesi pt base averag dcf wacc t-
growth ri assumpt dcf ddm coe impli
growth target price-to-earnings multipl base peer averag
upsid risk weak sterl fall raw materi price recoveri eu person care
downsid risk strong sterl benign raw materi increas competit collaps
valuat thesi gbp pt blend averag ri gbp wacc
termin growth dcf gbp assumpt ri ddm gbp coe
rv gbp histor averag price-to-earnings
upsid risk faster expect volum sale growth core peek busi invibio
gain favour currenc movement decis leverag balanc sheet
effect aggress cash return real ramp-up
competit landscap and/or acceler new applic pipelin
downsid risk potenti neg currenc impact dip demand lead
phase de-stock slow invibio growth penetr rate medic applic
materialis time manner
valuat methodolog wacker chemi price target base blend
averag dcf model wacc termin growth residu incom
analysi assumpt dcf sum part use peer-group
ev/ebitda multipl dividend discount model coe use
long-term retent ratio dcf ri sop model incorpor valu
siltron per share
upsid risk better mix chemic higher oper leverag assum
ebitda level tennesse higher polysilicon price higher siltron share price
sustain tight siloxan acceler specialis
downsid risk lower polysilicon price lower level solar instal polysilicon
plant utilis prolong construct downturn euro appreci vs
renminbi lower siltron share price cyclic downturn silcon segment
 co plc act financi advisor
solvay solvay relat divestur solvay polyamid asset basf
announc septemb solvay agre pay fee
financi servic pleas refer note end report
act financi advisor omnova solut inc omnova
relat definit agreement provid sale omnova synthom plc
synthom announc juli propos transact subject
approv sharehold omnova synthom regulatori approv
customari close condit report inform provid herein
intend provid vote advic ii serv endors propos
transact iii result procur withhold revoc proxi
action secur holder omnova agre pay fee
financi servic includ transact fee conting upon
consumm transact pleas refer note end report
